KR101497509B1 - 트라마돌의 부작용을 감소시키는 방법 - Google Patents

트라마돌의 부작용을 감소시키는 방법 Download PDF

Info

Publication number
KR101497509B1
KR101497509B1 KR1020097018879A KR20097018879A KR101497509B1 KR 101497509 B1 KR101497509 B1 KR 101497509B1 KR 1020097018879 A KR1020097018879 A KR 1020097018879A KR 20097018879 A KR20097018879 A KR 20097018879A KR 101497509 B1 KR101497509 B1 KR 101497509B1
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
acceptable salt
tramadol
combination
sildenafil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020097018879A
Other languages
English (en)
Korean (ko)
Other versions
KR20090127277A (ko
Inventor
데이비드 바-오
케빈 빌야드
제임스 브이. 윙클러
Original Assignee
브릭스 파마슈티컬스 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브릭스 파마슈티컬스 인코퍼레이티드 filed Critical 브릭스 파마슈티컬스 인코퍼레이티드
Publication of KR20090127277A publication Critical patent/KR20090127277A/ko
Application granted granted Critical
Publication of KR101497509B1 publication Critical patent/KR101497509B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020097018879A 2007-02-12 2008-02-12 트라마돌의 부작용을 감소시키는 방법 Active KR101497509B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88938007P 2007-02-12 2007-02-12
US60/889,380 2007-02-12
PCT/US2008/053722 WO2008100933A2 (en) 2007-02-12 2008-02-12 Reducing side effects of tramadol

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020137027225A Division KR20130122023A (ko) 2007-02-12 2008-02-12 트라마돌의 부작용을 감소시키는 방법

Publications (2)

Publication Number Publication Date
KR20090127277A KR20090127277A (ko) 2009-12-10
KR101497509B1 true KR101497509B1 (ko) 2015-03-03

Family

ID=39690762

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137027225A Withdrawn KR20130122023A (ko) 2007-02-12 2008-02-12 트라마돌의 부작용을 감소시키는 방법
KR1020097018879A Active KR101497509B1 (ko) 2007-02-12 2008-02-12 트라마돌의 부작용을 감소시키는 방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020137027225A Withdrawn KR20130122023A (ko) 2007-02-12 2008-02-12 트라마돌의 부작용을 감소시키는 방법

Country Status (16)

Country Link
US (3) US20080261991A1 (enExample)
EP (2) EP2114147B9 (enExample)
JP (1) JP5550101B2 (enExample)
KR (2) KR20130122023A (enExample)
CN (1) CN101674728A (enExample)
AU (1) AU2008216363B2 (enExample)
BR (1) BRPI0807281A2 (enExample)
CA (1) CA2677691C (enExample)
DK (1) DK2114147T3 (enExample)
ES (1) ES2384127T3 (enExample)
MX (1) MX2009008511A (enExample)
NZ (1) NZ579170A (enExample)
PL (1) PL2114147T3 (enExample)
SG (1) SG178775A1 (enExample)
WO (1) WO2008100933A2 (enExample)
ZA (1) ZA200906187B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2677690C (en) * 2007-02-12 2012-05-15 James V. Winkler Treatment of comorbid premature ejaculation and erectile dysfunction
KR20130122023A (ko) * 2007-02-12 2013-11-06 디엠아이 바이오사이언시스 인코포레이티드 트라마돌의 부작용을 감소시키는 방법
CA2785056A1 (en) 2009-12-22 2011-07-21 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
CA2833307C (en) 2011-04-12 2018-01-23 Revogenex Inc. Intravenous administration of tramadol
WO2015134695A1 (en) * 2014-03-07 2015-09-11 Vyrix Pharmaceuticals, Inc. Method of mitigating the side effects of a phosphodiesterase type v inhibitor in a subject
US20160228485A1 (en) * 2015-02-11 2016-08-11 Latasha M. Watts Skin medicating system
US9693949B1 (en) 2015-12-22 2017-07-04 Revogenex Ireland Ltd Intravenous administration of tramadol
US9980900B2 (en) 2015-12-22 2018-05-29 Revogenex Ireland Ltd Intravenous administration of tramadol
US10022321B2 (en) 2016-06-30 2018-07-17 Revogenex Ireland Ltd. Intravenous administration of tramadol
WO2020006606A1 (en) * 2018-07-05 2020-01-09 Helium 3 Resources Pty Ltd A pharmaceutical composition and method of use of same
WO2022026591A1 (en) * 2020-07-29 2022-02-03 Kydes Pharmaceuticals, Llc Pharmaceutical formulations comprising tadalafil
US11504332B2 (en) 2021-03-23 2022-11-22 Vk Research Associates Inc. Phosphodiesterase-4 inhibitor combinations, methods of making, and methods of use thereof
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
KR20040052490A (ko) * 2001-03-16 2004-06-23 디엠아이 바이오사이언스 인코포레이티드 사정 지연 방법
US6765010B2 (en) * 1999-05-06 2004-07-20 Pain Therapeutics, Inc. Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3830934A (en) 1967-07-27 1974-08-20 Gruenenthal Chemie Analgesic and antitussive compositions and methods
US3652589A (en) 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
US4127118B1 (en) 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
EP0526566B1 (en) 1990-04-25 1998-11-25 Vivus, Inc. Treatment of erectile dysfunction
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5151448A (en) 1991-07-12 1992-09-29 Crenshaw Roger T Method for treating premature ejaculation
ATE169498T1 (de) 1991-09-06 1998-08-15 Mcneilab Inc Zusammensetzung, die eine tramadol-verbindung und acetaminophen enthält, und ihre verwendung
US5223541A (en) 1991-09-13 1993-06-29 Mcneilab, Inc. Tramadol n-oxide material, enantiomers and compositions thereof, and their use
US20010006967A1 (en) 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US5472943A (en) * 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
IL119660A (en) 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
DE4329794C2 (de) * 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US5861431A (en) 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US6017963A (en) 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
DE19601744C2 (de) 1996-01-19 1998-04-16 Gruenenthal Gmbh Verfahren zur Herstellung der Enantiomeren von O-Demethyltramadol
DE19601745C1 (de) 1996-01-19 1997-10-09 Gruenenthal Gmbh Verfahren zur Racematspaltung von Tramadol
IL119121A (en) 1996-08-22 2000-11-21 Chemagis Ltd Process for the purification of (RR-SS)-2-dimethylaminomethyl-1-(3-methoxyphenyl)cyclohexanol hydrochloride
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
CN1251987A (zh) * 1997-03-11 2000-05-03 达尔文发现有限公司 含有r－和s－对映体分离部分的剂型
DE69830728T2 (de) 1997-04-11 2006-05-18 Nippon Shinyaku Co., Ltd. Arzneimittel zur behandlung von häufigem wasserlassen und harninkontinenz
US6037360A (en) 1997-10-28 2000-03-14 Vivus, Incorporated Administration of 5-HT3 receptor antagonists to treat premature ejaculation
DK1174431T3 (da) 1997-11-12 2012-08-20 Bayer Pharma AG 2-phenyl-substitueret imidazo triazinon som phoshodiesterase-inhibitorer
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
CN1204890C (zh) * 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
ES2412409T3 (es) * 1997-12-22 2013-07-11 Euro-Celtique S.A. Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo
US6339826B2 (en) * 1998-05-05 2002-01-15 International Business Machines Corp. Client-server system for maintaining a user desktop consistent with server application user access permissions
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
US6156342A (en) 1998-05-26 2000-12-05 Andex Pharmaceuticals, Inc. Controlled release oral dosage form
US6403605B1 (en) * 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6339106B1 (en) * 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
IL142778A0 (en) 1998-12-02 2002-03-10 Darwin Discovery Ltd Therapeutic product and its use
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
US6943166B1 (en) 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
US20030055070A1 (en) * 1999-07-01 2003-03-20 Wilma Harrison Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
WO2001034125A2 (en) * 1999-11-09 2001-05-17 Darwin Discovery Limited Therapeutic use and formulation of (-)-tramadol
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
US20030004177A1 (en) * 2001-05-11 2003-01-02 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US7914818B2 (en) * 2001-08-06 2011-03-29 Purdue Pharma L.P. Opioid agonist formulations with releasable and sequestered antagonist
US7019010B2 (en) * 2001-09-27 2006-03-28 Novertis Ag Combinations
US6943171B2 (en) * 2001-11-09 2005-09-13 Schering Corporation Polycyclic guanine derivative phosphodiesterase V inhibitors
WO2003072043A2 (en) * 2002-02-25 2003-09-04 Smithkline Beecham Corporation A method of recuding anti-neoplastic agent induced side effects
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US20050054688A1 (en) * 2003-08-08 2005-03-10 Pfizer Inc Selective serotonin reuptake inhibitors in the treatment of disease
US20060149480A1 (en) * 2004-02-26 2006-07-06 Lundeen James E Method of making combination medicament and medicament made thereby
JP4475098B2 (ja) * 2004-11-02 2010-06-09 ソニー株式会社 記憶素子及びその駆動方法
MX2007010721A (es) * 2005-03-01 2007-11-13 Pfizer Ltd Nuevo uso de inhibidores de fosfodiesterasa 7 para el tratamiento de dolor neuropatico.
MX2008007589A (es) * 2005-12-13 2009-01-27 Trinity Lab Inc Un metodo para tratar eyaculacion prematura en seres humanos.
US20070185145A1 (en) * 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
KR20130122023A (ko) * 2007-02-12 2013-11-06 디엠아이 바이오사이언시스 인코포레이티드 트라마돌의 부작용을 감소시키는 방법
CA2677690C (en) * 2007-02-12 2012-05-15 James V. Winkler Treatment of comorbid premature ejaculation and erectile dysfunction
US20100120780A1 (en) * 2007-04-19 2010-05-13 Chandra Ulagaraj Singh Treatments for premature ejaculation in humans

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6765010B2 (en) * 1999-05-06 2004-07-20 Pain Therapeutics, Inc. Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
KR20040052490A (ko) * 2001-03-16 2004-06-23 디엠아이 바이오사이언스 인코포레이티드 사정 지연 방법

Also Published As

Publication number Publication date
WO2008100933A2 (en) 2008-08-21
EP2114147B9 (en) 2013-04-10
EP2486921A1 (en) 2012-08-15
WO2008100933A3 (en) 2008-10-16
PL2114147T3 (pl) 2012-10-31
CA2677691C (en) 2012-07-31
US20080261991A1 (en) 2008-10-23
MX2009008511A (es) 2010-01-20
BRPI0807281A2 (pt) 2014-04-29
HK1131730A1 (en) 2010-02-05
NZ579170A (en) 2012-05-25
DK2114147T3 (da) 2012-06-25
JP5550101B2 (ja) 2014-07-16
EP2114147B1 (en) 2012-05-16
JP2010518168A (ja) 2010-05-27
SG178775A1 (en) 2012-03-29
AU2008216363B2 (en) 2014-05-08
EP2114147A4 (en) 2010-04-07
AU2008216363A1 (en) 2008-08-21
KR20130122023A (ko) 2013-11-06
US20120018333A1 (en) 2012-01-26
KR20090127277A (ko) 2009-12-10
CA2677691A1 (en) 2008-08-21
CN101674728A (zh) 2010-03-17
ZA200906187B (en) 2013-02-27
US20130338166A1 (en) 2013-12-19
EP2114147A2 (en) 2009-11-11
ES2384127T3 (es) 2012-06-29

Similar Documents

Publication Publication Date Title
KR101497509B1 (ko) 트라마돌의 부작용을 감소시키는 방법
CA2657043A1 (en) Use of flibanserin for the treatment of sexual disorders in females
KR20150089085A (ko) 조루 및 발기부전을 동시에 치료하는 방법
KR20040052490A (ko) 사정 지연 방법
TWI907146B (zh) 3-[(苯並[d][1,3]二氧戊環-4-基)-氧基]-3-芳基丙胺類化合物在製備治療性功能障礙的藥物中的用途
WO2025245066A1 (en) Compositions and methods for affecting weight loss, weight management, sexual disorders, well-being, self-esteem, and/or self-confidence
HK1131730B (en) Reducing side effects of tramadol
HK1132882B (en) Treatment of comorbid premature ejaculation and erectile dysfunction
HK1128226B (en) Pharmaceutical combinations comprising testosterone in the treatment of female sexual dysfunction

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090909

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110531

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130315

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20131015

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140224

Patent event code: PE09021S01D

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20140811

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20141124

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20150224

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20150225

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20180817

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20180817

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20190221

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20190221

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20201229

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20210401

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20220329

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20230314

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20240327

Start annual number: 11

End annual number: 11